Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824727 | Clinical Therapeutics | 2015 | 12 Pages |
Abstract
All patients with a belimumab prescription had an SLE diagnosis on at least 1 medical claim, and the vast majority of those meeting all eligibility criteria had previously used a standard SLE therapy. Disease severity improved for a number of patients while on belimumab treatment and modest corticosteroid dose reductions were observed in later months. After initiating belimumab, health care costs (excluding belimumab) decreased. GlaxoSmithKline Clinical Study Register Study ID: 114955.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Xuehua MA, PhD, Debra F. MS, PhD, Alan MPH, Jeetvan PhD, Hong PhD, Robert PhD,